A triple action CDK4/6-PI3K-BET inhibitor with augmented cancer cell cytotoxicity.

Autor: Burgoyne AM; Division of Hematology-Oncology, Department of Medicine, Moores Cancer Center, University of California San Diego, La Jolla, CA USA., Vann KR; Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO USA., Joshi S; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Moores Cancer Center, University of California San Diego, La Jolla, CA USA., Morales GA; SignalRx Pharmaceuticals, San Diego, CA USA., Vega FM; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Moores Cancer Center, University of California San Diego, La Jolla, CA USA.; Department of Cell Biology, Instituto de Biomedicina de Sevilla, Universidad de Sevilla, Sevilla, Spain., Singh A; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Moores Cancer Center, University of California San Diego, La Jolla, CA USA., Pal D; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Moores Cancer Center, University of California San Diego, La Jolla, CA USA., Merati AB; Division of Hematology-Oncology, Department of Medicine, Moores Cancer Center, University of California San Diego, La Jolla, CA USA., Kutateladze TG; Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO USA., Durden DL; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Moores Cancer Center, University of California San Diego, La Jolla, CA USA.; SignalRx Pharmaceuticals, San Diego, CA USA.

Publikováno v: Cell discovery [Cell Discov] 2020 Jul 28; Vol. 6 (1), pp. 49. Date of Electronic Publication: 2020 Jul 28 (Print Publication: 2020).